VALOR DE LA INVESTIGACION INVASIVA Y NO INVASIVA EN LA EVALUACION PREOPERATORIA DE LA HIPERPLASIA PROSTATICA BENIGNA. PERSPECTIVAS DEL ANALISIS PRONOSTICO EN LA EVALUACION CLINICA DE LA HIPERPLASIA PROSTATICA BENIGNA

(especial para SIIC © Derechos reservados)
A través del puntaje del International Prostate Symptoms Score y de la medición de Qmáx sería posible predecir el resultado de la cirugía de resección transuretral de la próstata.
porru9.jpg Autor:
Porru d
Columnista Experto de SIIC
Artículos publicados por Porru d
Coautores
Salvatore Stancati MD*  Giovanni L. Giliberto MD*  Matteo Gerardini MD*  Bruno Rovereto MD* 
Divisione Urologia, IRCCS Policlinico S. Matteo, Pavia, Italia*
Recepción del artículo
12 de Febrero, 2004
Primera edición
1 de Abril, 2004
Segunda edición, ampliada y corregida
7 de Junio, 2021

Resumen
Objetivo. Evaluar el valor predictivo de la combinación del International Prostate Symptoms Score (IPSS), la flujometría de orina y la ecografía para la determinación de la obstrucción al flujo vesical (OFV) y la predicción de resultado. Métodos. Fueron evaluados 45 individuos de un grupo de 60 pacientes con hiperplasia prostática benigna. Los criterios de selección para la cirugía fueron IPSS < 16 y Qmáx <10 ml/seg. Se realizó resección transuretral de la próstata (RTUP). Se definió como éxito en el tratamiento al Qmáx por encima de 15 ml/seg, volumen residual de orina de menos de 100 ml, reducción del 50% en IPSS, y ausencia de retención urinaria. Resultados. Se encontraron anomalías urodinámicas en 93.3% de los pacientes: 19 tenían inestabilidad del detrusor, 5 deterioro de la contractilidad, 37 OFV comprobado, y 8 obstrucción leve o ausente. La tasa general de éxito fue del 86% cuando se midió a través de IPSS. Su valor cayó en forma significativa (p = 0.005). El puntaje mejoró significativamente luego de la cirugía sólo en el grupo con obstrucción comparado con el grupo sin obstrucción (p = 0.001). Conclusiones. Una alta proporción de pacientes operados en forma exitosa (71.1%) tenía la combinación de IPSS >16 y Qmáx < 10 ml/seg, si bien la OFV no pudo ser predicha con precisión usando sólo métodos no invasivos. Los pacientes con obstrucción infravesical leve o ausente sólo tuvieron una mejoría mínima del IPSS y de la flujometría de orina luego de la cirugía.

Palabras clave
Flujometría de orina, IPSS, volumen residual de orina, obstrucción al flujo vesical, hiperplasia prostática benigna, estudio de presión de flujo


Artículo completo

(castellano)
Extensión:  +/-8.09 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Abstract
Aim: Evaluate the predictive value of a combination of IPSS, uroflowmetry and ultrasound determination of residual urine volume compared to pressure-flow study in the determination of bladder outflow obstruction (BOO) and in predicting treatment outcome. Methods: Forty-five out of a group of 60 BPH symptomatic patients were evaluated. Selection criteria for surgery were IPSS>16 and Qmax<10 ml/s. Transurethral resection of the prostate (TURP) was performed. Treatment success was defined as Qmax above 15 ml/s, residual urine of less than 100 ml, a 50% reduction in IPSS and absence of urinary retention. Results: Urodynamic abnormalities were found in 93.3% of patients: 19 had detrusor instability, 5 patients showed impaired contractility, 37 patients had proven BOO, and 8 patients were unobstructed or mildly obstructed. The overall success rate was 86% when measured by the IPSS. Its value dropped significantly (P=0.005). The score improved significantly after surgery only in the obstructed group compared to the non-obstructed group (P=0.001).Conclusions: A high proportion of patients successfully operated (71.1%) had a combination of IPSS>16 and Qmax<10 ml/s, although BOO could not be accurately predicted with non-invasive methods alone. Patients with no or mild infravesical obstruction had only minimal improvement of IPSS and uroflowmetry following surgery. Content main subject: Diagnostic evaluation of BPH.

Key words
uroflowmetry, IPSS, residual urine volume, BOO, BPH, pressure-flow study


Full text
(english)
para suscriptores/ assinantes

Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Urología
Relacionadas: Diagnóstico por Imágenes, Medicina Interna



Comprar este artículo
Extensión: 8.09 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Bibliografía del artículo
  1. M. Emberton, D.E. Neal and N. Black , The National Prostatectomy Audit: the clinical management of patients during hospital admission. Br. J. Urol. 75 (1995), pp. 301-316.
  2. O.W. Hakenberg, C.B. Pinnock and V.R. Marshall , Does evaluation with the International Prostate Symptom Score predict the outcome of transurethral resection of the prostate. J. Urol. 158 (1997), pp. 94-99.
  3. W. Schäfer, F. Waterbar, P.H. Langen and F.J. Deutz , A simplified graphic procedure for detailed analysis of detrusor and outlet function during voiding. Neurourol. Urodynam. 8 (1989), pp. 405-407. Abstract-ScienceDirect Navigator
  4. N.R. Netto, Jr., C.A.L. D'Ancona and M.L. de Lima , Correlation between the International Prostate Symptom Score and a pressure-flow study in the evaluation of symptomatic benign prostatic hyperplasia. J. Urol. 155 (1996), pp. 200-204.
  5. K. Ameda, G.S. Steele, M.P. Sullivan et al., Detrusor contraction duration as a urodynamic parameter of bladder outlet obstruction for evaluating men with lower urinary tract symptoms. J. Urol. 160 (1998), pp. 482-487.
  6. P.H. Abrams, D.J. Farrar, W.R.T. Turner, C.G. Whiteside and R.C.L. Feneley , The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients. J. Urol. 121 (1979), pp. 640-643.
  7. D.E. Neal, P.D. Ramsden, L. Sharples, A. Smith, P.H. Powell, R.A. Styles et al., Outcome of elective prostatectomy. Br. Med. J. 299 (1989), pp. 762-764.
  8. M.J.F.J. Barry, Jr., M.P. O'Leary, R.C. Bruskewitz, H.L. Holtgrewe and W.K. Mebust , Cockett ATK and the Measurement Committee of the American Urological Association symptom index for benign prostatic hyperplasia. J. Urol. 148 (1992), pp. 1549-1552.
  9. Horninger W, Janetschek G, Pointner J, Watson G, Bartsch G. Are TULIP interstitial laser and contact laser superior to TURP. J Urol 1995;153(part 2):413A [Abstract 738].
  10. M.J. Barry, A.T.K. Cockett, H.L. Holtgrewe, J.D. McConnell, S.A. Sihelnik and H.N. Winfield , Relationship of symptoms of prostatism of commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J. Urol. 150 (1993), pp. 351-354.
  11. G.S. Steele, M.P. Sullivan, D.J. Sleep and S.V. Yalla , Combination of symptom score, flow rate and prostate volume for predicting bladder outflow obstruction in men with lower urinary tract symptoms. J. Urol. 164 (2000), pp. 344-348. Abstract-ScienceDirect Navigator
  12. J.L.K.R. Bosch, W.C.J. Hop, W.J. Kirkels and F.H. Schroder , The International Prostate Symptom Score in a community-based sample of men between 55 and 74 years of age: prevalence and correlation of symptoms with age prostate volume flow rate and residual urine volume. Br. J. Urol. 75 (1995), pp. 622-626.
  13. Koyanagi T, Artibani W, Correa R, et al. Initial diagnostic evaluation of men with lower urinary tract symptoms. In: Denis L, Griffiths K, Koury S, et al., editors. Proceedings of the Fourth International Consultation on Benign Prostatic Hyperplasia (BPH), vol. 4. United Kingdom: Plymbridge Distributors Ltd., 1998. p. 209.
  14. McConnell JD, Roehrborn CG, Slawin KM, et al. Baseline measures predict the risk of benign prostatic hyperplasia clinical progression in placebo-treated patients. Program and abstracts of the American Urological Association 98th Annual Meeting; April 26-May 1, 2003; Chicago, Illinois. Abstract 1287.
  15. Roehrborn CG, Boyle P, Nickel JC. PSA is a significant predictor of objective parameters in men at risk for BPH progression. Program and abstracts of the American Urological Association 98th Annual Meeting; April 26-May 1, 2003; Chicago, Illinois. Abstract 1361.
  16. Roehrborn CG, McConnell J, Bonilla J, et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. J Urol. 2000;163:13-20.
  17. Kaplan SA, Roehrborn CG, McConnell JD, et al. Baseline symptoms, uroflow, and post-void residual urine as predictors of bph clinical progression in the medically treated arms of the MTOPS trial. Program and abstracts of the American Urological Association 98th Annual Meeting; April 26-May 1, 2003; Chicago, Illinois. Abstract 1289.
  18. Kirby RS, Roehrborn C, Boyle P, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the prospective European doxazosin and combination therapy (PREDICT) trial. Urology. 2003;61:119-126.
  19. Roehrborn CG. Proportion of patients from the PREDICT trial with at least a 4-point rise in international prostate symptom score at 1 year. Program and abstracts of the American Urological Association 98th Annual Meeting; April 26-May 1, 2003; Chicago, Illinois. Abstract 1291.
  20. Boyle P, Robertson C, Wilson TH, et al. Predictive model for acute urinary retention in men with benign prostatic hyperplasia. Program and abstracts of the American Urological Association 98th Annual Meeting; April 26-May 1, 2003; Chicago, Illinois. Abstract 1293.
  21. Kattan MW, Wilson TH, Roehrborn CG, et al. Development of a nomogram to predict bph progression with or without dutasteride therapy. Program and abstracts of the American Urological Association 98th Annual Meeting; April 26-May 1, 2003; Chicago, Illinois. Abstract 1781.

Título español
Resumen
 Palabras clave
 Bibliografía
 Artículo completo
(exclusivo a suscriptores)
 Autoevaluación
  Tema principal en SIIC Data Bases
 Especialidades

 English title
 Abstract
 Key words
Full text
(exclusivo a suscriptores)

Autor 
Artículos
Correspondencia

Patrocinio y reconocimiento
Imprimir esta página
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Inicio/Home

Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008